Quantum BioPharma Launched Phase 2 Trial for Lucid-MS
The clinical trial evaluates a PAD2-targeting therapy aimed at reversing myelin degradation in sclerosis patients.
Updated on Oct. 6, 2026 in Quantum Computing
Live Poll
Do you trust that new pharmaceutical developments significantly improve outcomes for those with chronic illnesses?
Quantum BioPharma has partnered with Thermo Fisher Scientific to initiate a Phase 2 clinical trial for Lucid-MS. This randomized, double-blind, placebo-controlled study assesses the safety and efficacy of a chemical entity designed to inhibit the PAD2 enzyme.
Why it matters
The trial aims to determine if targeting the PAD2 enzyme can effectively halt or reverse the myelin degradation that characterizes progressive multiple sclerosis. This development follows preclinical research suggesting the therapy could address disease pathology.
The study targets the PAD2 enzyme to stop myelin breakdown. Efficacy is being monitored through clinical and radiological markers, including imaging with the [18F]3F4AP PET tracer.
The players
Quantum BioPharma
A pharmaceutical company developing chemical entities for neurological conditions.
Thermo Fisher Scientific
A global life sciences firm whose PPD clinical research business manages trial operations and site management.
The details
Lucid-MS functions by targeting PAD2 — an enzyme linked to protein citrullination that contributes to myelin damage. The trial utilizes a randomized, double-blind, placebo-controlled architecture, which prevents both participants and researchers from knowing who receives the active drug versus a neutral placebo until the study concludes. Effectiveness is gauged by tracking physiological recovery via radiological imaging and clinical status metrics.
Timeline
May 2026: Patient enrollment reached 50% capacity.
October 6, 2026: Quantum BioPharma announced the partnership with Thermo Fisher Scientific.
The Tech Race
This study advances the therapeutic class of PAD2-enzyme inhibitors within the broader neurodegenerative drug pipeline. It follows established pharmaceutical precedent for scaling chemical entities from preclinical myelin-reversal results to human safety and efficacy testing.
The study is currently enrolling patients in the United States to assess drug tolerance and efficacy. It replaces earlier preclinical testing stages and represents the next step toward potential clinical availability for individuals with progressive multiple sclerosis.
The takeaway
The progression of Lucid-MS into Phase 2 testing serves as a critical benchmark for the viability of PAD2-targeted treatments. Observers should track subsequent radiological reports and final clinical outcomes to determine if the drug effectively reverses myelin degradation in human subjects.
Further reading
Learn more about the latest research in this sector at Quantum Computing.
Live Poll
Do you trust that new pharmaceutical developments significantly improve outcomes for those with chronic illnesses?
